Peter Greenleaf

Peter Greenleaf

Chairman at
Maryland Venture Fund

Net worth: 29 M $ as of 31/05/2026

56 year
Health Technology
Finance
Commercial Services

Profile

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
02/03/2026 18,40,379 ( 1.43% ) 28 M $ 31/05/2026
0.71%
02/04/2026 24,681 ( 0.71% ) 653 306 $ 31/05/2026

Latest news about Peter Greenleaf

Peter Greenleaf active positions

CompaniesPositionStart
Chairman -
Chairman 17/12/2020
Consultant / Advisor -

Former positions of Peter Greenleaf

CompaniesPositionEnd
AURINIA PHARMACEUTICALS INC. Chief Executive Officer 23/03/2026
ANTARES PHARMA, INC. Director/Board Member 24/05/2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Chairman 22/03/2022
AVALO THERAPEUTICS, INC. Chief Executive Officer 15/04/2019
KIORA PHARMACEUTICALS, INC. Director/Board Member 03/01/2020
See the detail of Peter Greenleaf's experience

Training of Peter Greenleaf

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

69

1st degree connections

33

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Peter Greenleaf
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!